CureVac Overview

  • Founded
  • 2000

  • Status
  • Public

  • Employees
  • 1,000

  • Stock Symbol
  • CVAC

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $8.04

  • (As of Thursday Closing)

CureVac General Information


CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • Friedrich-Miescher-Strabe 15
  • 72076 Tubingen
  • Germany
+49 07071 00000

CureVac Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CureVac Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.04 $8.22 $6.99 - $55.54 $1.54B 187M 420K -$1.31

CureVac Financials Summary

In Thousands,
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 1,852,253 5,243,763 13,414,812
Revenue 129,601 121,765 55,709 19,496
EBITDA (223,505) (468,887) (113,016) (103,363)
Net Income (246,216) (486,771) (147,188) (111,802)
Total Assets 967,106 1,311,386 1,858,918 146,317
Total Debt 42,002 32,712 37,006 88,659
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CureVac Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CureVac‘s full profile, request access.

Request a free trial

CureVac Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenge
Drug Discovery
Tubingen, Germany
1,000 As of 2022
00000000 00.000


d minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
Mainz, Germany
0000 As of 0000
00000000 00.000


ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
Utrecht, Netherlands
00 As of 0000
0000000000 0 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CureVac Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioNTech Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
You’re viewing 2 of 2 competitors. Get the full list »

CureVac Patents

CureVac Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220202930-A1 Rna vaccine against sars-cov-2 variants Pending 22-Dec-2020 000000000 0
US-20220218815-A1 Coronavirus vaccine Pending 10-Nov-2020 0000000000
US-11241493-B2 Coronavirus vaccine Active 10-Nov-2020 000000000
US-20220193226-A1 Coronavirus vaccine Pending 10-Nov-2020 0000000000
US-20210379181-A1 Coronavirus vaccine Active 10-Nov-2020 A61K39/215
To view CureVac’s complete patent history, request access »

CureVac Executive Team (21)

Name Title Board Seat Contact Info
Franz-Werner Haas Ph.D Chief Executive Officer
Pierre Kemula Chief Financial Officer, Finance
Malte Greune Chief Operating Officer, Operations
Igor Splawski Chief Scientific Officer
Antony Blanc Ph.D Executive
You’re viewing 5 of 21 executive team members. Get the full list »

CureVac Board Members (10)

Name Representing Role Since
Christof Hettich Ph.D dievini Board Member 000 0000
Craig Tooman Self Board Member 000 0000
Friedrich von Bohlen und Halbach Ph.D Self Board Member & Vice Chairman 000 0000
Ingmar Hoerr Ph.D CureVac Board Member 000 0000
Jean Stéphenne CureVac Chairman 000 0000
You’re viewing 5 of 10 board members. Get the full list »

CureVac Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CureVac Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CureVac‘s full profile, request access.

Request a free trial

CureVac Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 08-Jun-2022 0000000000 0000 Biotechnology 00000-000
To view CureVac’s complete acquisitions history, request access »

CureVac Subsidiaries (1)

Company Name Industry Location Founded
00000 000000000000 Biotechnology Amsterdam, Netherlands 0000
To view CureVac’s complete subsidiaries history, request access »